INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 13, 2013 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,063 | -- | 239,063 |
| Dec 14, 2012 |
Director, EVP CSO Pres Regen Res Labs
Trans History: 673
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,063 | -- | 239,063 |
| Aug 06, 2021 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | $52.03 | 573,321 |
| Aug 06, 2021 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | -- | 160,000 |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | $52.03 | 880,938 |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | -- | 158,079 |
| Dec 16, 2014 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 240,000 | -- | 400,000 |
| Dec 16, 2014 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 240,000 | -- | 398,079 |
| Dec 19, 2017 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Bona fide gift | 242,150 | -- | 847 |
| Dec 19, 2017 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Bona fide gift | 242,150 | -- | 486,820 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.